EP3333157A4 - Composés vinyliques utilisés comme inhibiteurs du fgfr et du vegfr - Google Patents
Composés vinyliques utilisés comme inhibiteurs du fgfr et du vegfr Download PDFInfo
- Publication number
- EP3333157A4 EP3333157A4 EP16834592.4A EP16834592A EP3333157A4 EP 3333157 A4 EP3333157 A4 EP 3333157A4 EP 16834592 A EP16834592 A EP 16834592A EP 3333157 A4 EP3333157 A4 EP 3333157A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- fgfr
- vinyl compounds
- vegfr inhibitors
- vegfr
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510484124 | 2015-08-07 | ||
CN201510908082 | 2015-12-09 | ||
PCT/CN2016/092989 WO2017024968A1 (fr) | 2015-08-07 | 2016-08-03 | Composés vinyliques utilisés comme inhibiteurs du fgfr et du vegfr |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3333157A1 EP3333157A1 (fr) | 2018-06-13 |
EP3333157A4 true EP3333157A4 (fr) | 2018-10-17 |
EP3333157B1 EP3333157B1 (fr) | 2020-12-23 |
Family
ID=57983012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16834592.4A Active EP3333157B1 (fr) | 2015-08-07 | 2016-08-03 | Composés vinyliques utilisés comme inhibiteurs du fgfr et du vegfr |
Country Status (5)
Country | Link |
---|---|
US (1) | US10519133B2 (fr) |
EP (1) | EP3333157B1 (fr) |
JP (1) | JP6898306B2 (fr) |
CN (1) | CN107922349B (fr) |
WO (1) | WO2017024968A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6803410B2 (ja) * | 2017-02-14 | 2020-12-23 | 富士フイルム株式会社 | インダゾール化合物の製造方法およびインダゾール化合物 |
CN116283940A (zh) * | 2017-12-07 | 2023-06-23 | 哈尔滨珍宝制药有限公司 | 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法 |
CN113490667B (zh) * | 2018-12-29 | 2023-10-27 | 盛世泰科生物医药技术(苏州)股份有限公司 | 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物 |
EP3919478A4 (fr) * | 2019-02-02 | 2022-12-07 | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. | Composé de vinylpyridine carboxamide utile en tant qu'immunomodulateur pd-l1 |
AU2020214518B2 (en) * | 2019-02-02 | 2022-12-15 | Novaonco Js Therapeutics Co., Ltd. | Fluorovinylbenzamide compound as PD-L1 immunomodulator |
CN113993867B (zh) * | 2019-06-14 | 2023-10-24 | 盛世泰科生物医药技术(苏州)股份有限公司 | 作为fgfr和vegfr双重抑制剂的并环类化合物 |
CN114072387B (zh) * | 2019-11-06 | 2024-03-08 | 暨南大学 | 吲唑类化合物及其药用组合物和应用 |
WO2021138391A1 (fr) * | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Composés d'indazole |
JP2023536603A (ja) * | 2020-08-11 | 2023-08-28 | ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド | Fgfr阻害剤化合物及びその使用 |
US20240109865A1 (en) * | 2020-12-30 | 2024-04-04 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
WO2023279041A1 (fr) * | 2021-06-30 | 2023-01-05 | Tyra Biosciences, Inc. | Composés indazoles |
WO2024006897A1 (fr) * | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Composés d'indazole |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053268A2 (fr) * | 2000-01-18 | 2001-07-26 | Agouron Pharmaceuticals, Inc. | Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020010137A1 (en) * | 1997-09-18 | 2002-01-24 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
EA006711B1 (ru) | 2000-09-11 | 2006-02-24 | Чирон Корпорейшн | Хинолиноновые производные в качестве ингибиторов тирозинкиназы |
EP1401831A1 (fr) | 2001-07-03 | 2004-03-31 | Chiron Corporation | Composes d'indazole benzimidazole utilises comme inhibiteurs de tyrosine et de serine/threonine kinase |
KR20050004214A (ko) | 2002-05-31 | 2005-01-12 | 에자이 가부시키가이샤 | 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물 |
WO2004050088A1 (fr) * | 2002-12-03 | 2004-06-17 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de jnk |
NZ540340A (en) * | 2002-12-19 | 2007-07-27 | Pfizer | 2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
WO2007058626A1 (fr) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Composes d'indazole |
CA2644910C (fr) * | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Composes d'indazole |
JO2860B1 (en) * | 2009-05-07 | 2015-03-15 | ايلي ليلي اند كومباني | Phenylendazolyl compounds |
-
2016
- 2016-08-03 EP EP16834592.4A patent/EP3333157B1/fr active Active
- 2016-08-03 US US15/750,704 patent/US10519133B2/en active Active
- 2016-08-03 JP JP2018507641A patent/JP6898306B2/ja active Active
- 2016-08-03 CN CN201680046188.0A patent/CN107922349B/zh active Active
- 2016-08-03 WO PCT/CN2016/092989 patent/WO2017024968A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053268A2 (fr) * | 2000-01-18 | 2001-07-26 | Agouron Pharmaceuticals, Inc. | Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire |
Non-Patent Citations (1)
Title |
---|
See also references of WO2017024968A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3333157B1 (fr) | 2020-12-23 |
WO2017024968A1 (fr) | 2017-02-16 |
CN107922349A (zh) | 2018-04-17 |
EP3333157A1 (fr) | 2018-06-13 |
US10519133B2 (en) | 2019-12-31 |
CN107922349B (zh) | 2021-05-07 |
US20180222886A1 (en) | 2018-08-09 |
JP2018531218A (ja) | 2018-10-25 |
JP6898306B2 (ja) | 2021-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1246794A1 (zh) | 作為fgfr抑制劑的雙環雜環 | |
EP3333157A4 (fr) | Composés vinyliques utilisés comme inhibiteurs du fgfr et du vegfr | |
EP3119772B8 (fr) | Inhibiteurs de syk de type hétéroaryle | |
EP3380101A4 (fr) | Composés inhibiteurs d'eif4-a et procédés associés | |
EP3184521A4 (fr) | Composés indazole utilisés comme inhibiteurs de la fgfr kinase, préparation et utilisation associées | |
EP3124482A4 (fr) | Dérivés de quinoléine comme inhibiteurs de smo | |
EP3248721A4 (fr) | Foret | |
EP3193600A4 (fr) | Inhibiteurs de smyd | |
EP3166608A4 (fr) | Composés aminopyridazinone à utiliser en tant qu'inhibiteurs de protéines kinases | |
EP3112570A4 (fr) | Ensemble fermeture de porte coulissante | |
EP3498706A4 (fr) | Composé hétérocyclique utilisé en tant qu'inhibiteur de fgfr | |
EP3195967A4 (fr) | Foret | |
EP3307271A4 (fr) | Procédés d'utilisation d'activateurs de la pyruvate kinase | |
EP3342514A4 (fr) | Mèche | |
EP3278911A4 (fr) | Mèche | |
EP3394068A4 (fr) | Inhibiteurs de tdo2 | |
EP3253390A4 (fr) | Composés d'aminoquinazoline comme antagonistes d'a2a | |
EP3110819A4 (fr) | Composés hétérocycliques | |
EP3489223A4 (fr) | Composé hétérocyclique utilisé en tant qu'inhibiteur de fgfr | |
EP3331532A4 (fr) | Composés d'aminoquinazoline substitués en tant qu'antagonistes d'a2a | |
EP3256450A4 (fr) | Composés pyrazole substitués utilisés en tant qu'inhibiteurs de rorgammat et utilisations desdits composés | |
EP3195966A4 (fr) | Foret | |
EP3272445A4 (fr) | Foret | |
EP3302486A4 (fr) | Composés de dihydropyrazolopyrimidinone utilisés comme inhibiteurs de pde2 | |
EP3193878A4 (fr) | Composés et méthodes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180307 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 401/02 20060101ALI20180618BHEP Ipc: C07D 405/14 20060101ALI20180618BHEP Ipc: C07D 403/02 20060101ALI20180618BHEP Ipc: A61P 35/00 20060101ALI20180618BHEP Ipc: C07D 235/02 20060101AFI20180618BHEP Ipc: A61K 31/395 20060101ALI20180618BHEP Ipc: C07D 401/14 20060101ALI20180618BHEP Ipc: C07D 401/12 20060101ALI20180618BHEP Ipc: C07D 413/14 20060101ALI20180618BHEP Ipc: A61K 31/416 20060101ALI20180618BHEP Ipc: C07D 403/14 20060101ALI20180618BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180914 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 401/12 20060101ALI20180911BHEP Ipc: C07D 403/02 20060101ALI20180911BHEP Ipc: C07D 235/02 20060101AFI20180911BHEP Ipc: C07D 405/14 20060101ALI20180911BHEP Ipc: C07D 401/02 20060101ALI20180911BHEP Ipc: C07D 413/14 20060101ALI20180911BHEP Ipc: A61K 31/416 20060101ALI20180911BHEP Ipc: A61P 35/00 20060101ALI20180911BHEP Ipc: C07D 403/14 20060101ALI20180911BHEP Ipc: C07D 401/14 20060101ALI20180911BHEP Ipc: A61K 31/395 20060101ALI20180911BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200703 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD. |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016050351 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1347577 Country of ref document: AT Kind code of ref document: T Effective date: 20210115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210324 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210323 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1347577 Country of ref document: AT Kind code of ref document: T Effective date: 20201223 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20201223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210323 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210423 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016050351 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210423 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |
|
26N | No opposition filed |
Effective date: 20210924 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210423 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20230821 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20230823 Year of fee payment: 8 Ref country code: IE Payment date: 20230822 Year of fee payment: 8 Ref country code: GB Payment date: 20230822 Year of fee payment: 8 Ref country code: CH Payment date: 20230902 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230825 Year of fee payment: 8 Ref country code: DE Payment date: 20230821 Year of fee payment: 8 Ref country code: BE Payment date: 20230821 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201223 |